⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XENE News
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
globenewswire.com
XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
globenewswire.com
XENE
Form 8-K
sec.gov
XENE
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
globenewswire.com
XENE
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
globenewswire.com
XENE
Form 8-K
sec.gov
XENE
Form 8-K
sec.gov
XENE
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
XENE
Drug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight
prnewswire.com
LIVN
PTC
UCB
XENE
AQST
TAK
BHVN
KNOP
VRTX
SUPN
GSK
SNY
MD
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas
globenewswire.com
GSK
RGNX
OMER
XENE
NMRA